CheckMate 205研究和CheckMate 039研究 CheckMate205研究是一个多队列、单臂2期的临床研究,研究纳入既往接受自体干细胞移植(HSCT)及移植后接受Adcetris治疗后病情复发或进展的经典霍奇金淋巴瘤(cHL)患者。 结果显示,客观有效率为为66%,6%的患者达到了完全缓解,60%的患者达到了部...
PD-1单药针对弥漫大B的有效率实在不高,施贵宝的PD-1抑制剂Opdivo为例,在代号为CheckMate-039的I期临床试验中,复发难治的弥漫大B的ORR是33%,中位缓解持续时间是22周,基本上没有CR,都是PR,现在研究方向是联合CAR T 或者 伊布替尼。弥散大B这种发病率不低预后又一般的,也是企业做临床会最先想到尝试大适应症...
对于非小细胞肺癌(NSCLC)中约占30%~40%的可手术患者[1],围术期治疗成为提高疗效的关键策略,尤其是近年来围术期免疫治疗的兴起,为其带来治疗新曙光。以CheckMate-159研究惊艳开局为序,伴随着新辅助Ⅲ期CheckMate-816研究和围术期...
伊匹木单抗)联用治疗初治黑色素瘤;CheckMate 017-二线治疗转移性鳞状非小细胞肺癌(NSCLC);CheckMate 057-二线治疗非鳞状NSCLC;CheckMate 032-治疗小细胞肺癌;CheckMate 025-治疗经治肾细胞癌;CheckMate214-与YERVOY联用治疗初治肾细胞癌;CheckMate-205/039-治疗经典霍奇金淋巴瘤;CheckMate 141-治疗...
In Checkmate 205 and 039, pneumonitis, including interstitial lung disease, occurred in 6.0% (16/266) of patients receiving OPDIVO. Immune-mediated pneumonitis occurred in 4.9% (13/266) of patients receiving OPDIVO, including Grade 3 (n=1) and Grade 2 (n=12). ...
Checkmate 205/039–classical Hodgkin lymphoma; Checkmate 141–recurrent or metastatic squamous cell carcinoma of the head and neck; Checkmate 275–previously treated advanced or metastatic urothelial carcinoma; ...
Checkmate 205/039–classical Hodgkin lymphoma; Checkmate 141–recurrent or metastatic squamous cell carcinoma of the head and neck; Checkmate 275–urothelial carcinoma; Checkmate 142–MSI-H or dMMR metastatic colorectal...
Describe your changes Made changes in input field in order to truncate the values The field text getting out when zoomed it (increased width as height is always 34) Briefly describe the changes y...
In Checkmate 205 and 039, pneumonitis, including interstitial lung disease, occurred in 6.0% (16/266) of patients receiving OPDIVO. Immune-mediated pneumonitis occurred in 4.9% (13/266) of patients receiving OPDIVO, including Grade 3 (n=1) and Grade 2 (n=12). ...
目的:新辅助免疫检查点抑制剂纳武利尤单抗联合伊匹木单抗可提高非小细胞肺癌(NSCLC)患者的总生存期(OS);然而,针对可切除肺癌的随机数据有限。我们报告了国际 III 期 CheckMate 816 试验中纳武利尤单抗联合伊匹木单抗与化疗的探索性随机分组研究结果...